Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;11(9):713-9.
doi: 10.1016/S1473-3099(11)70034-2.

Antiscience and ethical concerns associated with advocacy of Lyme disease

Affiliations

Antiscience and ethical concerns associated with advocacy of Lyme disease

Paul G Auwaerter et al. Lancet Infect Dis. 2011 Sep.

Abstract

Advocacy for Lyme disease has become an increasingly important part of an antiscience movement that denies both the viral cause of AIDS and the benefits of vaccines and that supports unproven (sometimes dangerous) alternative medical treatments. Some activists portray Lyme disease, a geographically limited tick-borne infection, as a disease that is insidious, ubiquitous, difficult to diagnose, and almost incurable; they also propose that the disease causes mainly non-specific symptoms that can be treated only with long-term antibiotics and other unorthodox and unvalidated treatments. Similar to other antiscience groups, these advocates have created a pseudoscientific and alternative selection of practitioners, research, and publications and have coordinated public protests, accused opponents of both corruption and conspiracy, and spurred legislative efforts to subvert evidence-based medicine and peer-reviewed science. The relations and actions of some activists, medical practitioners, and commercial bodies involved in Lyme disease advocacy pose a threat to public health.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

PGA has served as a consultant for Oxford Diagnostics and has participated in expert testimony in two medicolegal suits about possible Lyme disease. He has equity interest in Johnson & Johnson, no products of which are referred to in this article. RJD is part owner of and has stock in Biopeptides Corporation, no product of which is referred to in this article, has received payment for providing expert testimony in malpractice cases and holds patents on vaccine and diagnostic technology with SUNY at Stony Brook Biopeptides. JSD has received support for travel to meetings from DiaSorin and has licence of US patent 5,955,359 to Focus Diagnostics; none of these declarations are directly related to the contents of this article. JJH has served as an expert witness in several medicolegal cases concerning Lyme disease and has equity in Abbott, Bristol-Myers Squibb, Johnson & Johnson, and Merck; no products from these companies are referred to in this article. EMcS was a former programme officer for Lyme disease at the US NIH. RBN has served as an expert witness in malpractice litigation involving Lyme disease. EDS is a board member of the American Lyme Disease Foundation, for which no compensation is received. He has reviewed medical records for the Metropolitan Life Insurance Company and has provided medicolegal testimony. GPW is a board member of the American Lyme Disease Foundation for which no compensation is received, has served as an expert witness in malpractice cases involving Lyme disease, has research grants from the NIH/Immunetics, BioRad, DiaSorin, and BioMerieux to study diagnostic tests for Lyme disease, none of which is mentioned in the manuscript, and has equity in Abbott, a company not known to have any approved product for Lyme disease. JSB, RJD, JSD, JJH, RBN, EDS, ACS, and GPW have served on the panel for the 2006 IDSA Lyme disease guidelines. JSB, SO’C, SKS, ACS, and AW declare that they have no conflicts of interest.

Comment in

  • Lyme disease antiscience.
    Huyshe-Shires S. Huyshe-Shires S. Lancet Infect Dis. 2012 May;12(5):361; author reply 362-3. doi: 10.1016/S1473-3099(12)70052-X. Lancet Infect Dis. 2012. PMID: 22541623 No abstract available.
  • Lyme disease antiscience.
    Perronne C. Perronne C. Lancet Infect Dis. 2012 May;12(5):361-2; author reply 362-3. doi: 10.1016/S1473-3099(12)70053-1. Lancet Infect Dis. 2012. PMID: 22541624 No abstract available.
  • Lyme disease antiscience.
    Tuttle C. Tuttle C. Lancet Infect Dis. 2012 May;12(5):362; author reply 362-3. doi: 10.1016/S1473-3099(12)70054-3. Lancet Infect Dis. 2012. PMID: 22541626 No abstract available.

References

    1. Kalichman S. Denying AIDS: conspiracy theories, pseudoscience, and human tragedy. NY, USA: Springer; 2009.
    1. Stricker RB. Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease. Clin Infect Dis. 2007;45:149–57. - PubMed
    1. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–34. - PubMed
    1. Wormser GP, O’Connell S. Treatment of infection caused by Borrelia burgdorferi sensu lato. Expert Rev Anti Infect Ther. 2011;9:245–60. - PubMed
    1. Dattwyler RJ, Wormser GP, Rush TJ, et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr. 2005;117:393–97. - PubMed

Publication types

Substances